(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
-1.36% ¥ 1 590.00
Live Chart Being Loaded With Signals
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally...
Stats | |
---|---|
Today's Volume | 18 700.00 |
Average Volume | 4 850.00 |
Market Cap | 5.74B |
EPS | ¥0 ( 2024-01-30 ) |
Next earnings date | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -23.87 |
ATR14 | ¥4.47 (0.28%) |
Nippon Chemiphar Co., Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nippon Chemiphar Co., Financials
Annual | 2022 |
Revenue: | ¥31.56B |
Gross Profit: | ¥8.19B (25.94 %) |
EPS: | ¥93.92 |
FY | 2022 |
Revenue: | ¥31.56B |
Gross Profit: | ¥8.19B (25.94 %) |
EPS: | ¥93.92 |
FY | 2022 |
Revenue: | ¥32.51B |
Gross Profit: | ¥9.07B (27.91 %) |
EPS: | ¥194.33 |
FY | 2021 |
Revenue: | ¥31.54B |
Gross Profit: | ¥11.44B (36.28 %) |
EPS: | ¥137.75 |
Financial Reports:
No articles found.
Nippon Chemiphar Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥30.00 | 2008-03-26 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | ¥1 040.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.76 | -- |
Div. Sustainability Score | 5.79 | |
Div.Growth Potential Score | 1.529 | |
Div. Directional Score | 3.66 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7970.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7198.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6454.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
5449.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4441.T | Ex Dividend Junior | 2023-10-30 | Annually | 0 | 0.00% | |
3636.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2882.T | Ex Dividend Junior | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
1663.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9755.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8804.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.00787 | 1.500 | -0.157 | -0.236 | [0 - 0.5] |
returnOnAssetsTTM | -0.00473 | 1.200 | -0.158 | -0.189 | [0 - 0.3] |
returnOnEquityTTM | -0.0130 | 1.500 | -1.255 | -1.883 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.43 | 0.800 | 2.86 | 2.29 | [1 - 3] |
quickRatioTTM | 1.563 | 0.800 | 5.51 | 4.41 | [0.8 - 2.5] |
cashRatioTTM | 0.747 | 1.500 | 6.96 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.344 | -1.500 | 4.27 | -6.41 | [0 - 0.6] |
interestCoverageTTM | -3.58 | 1.000 | -2.44 | -2.44 | [3 - 30] |
operatingCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.934 | -1.500 | 6.26 | -9.40 | [0 - 2.5] |
grossProfitMarginTTM | 0.251 | 1.000 | 9.15 | 9.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0153 | 1.000 | -2.31 | -2.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.164 | 1.000 | -0.199 | -0.199 | [0.2 - 2] |
assetTurnoverTTM | 0.601 | 0.800 | 9.33 | 7.46 | [0.5 - 2] |
Total Score | 5.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -24.14 | 1.000 | -2.54 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0130 | 2.50 | -0.807 | -1.883 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.10 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.589 | 1.500 | -7.26 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0939 | 1.000 | -0.153 | 0 | [0.1 - 0.5] |
Total Score | 1.529 |
Nippon Chemiphar Co.,
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators